Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc.

A total of 144,000 adults could lose SNAP eligibility entirely, while 316,000 adults could see a reduction in benefits.

Also: A Medicare crisis and doctors’ concerns with Kennedy’s new coronavirus vaccine policy.

UnitedHealthcare and Optum's struggles with an evolving Medicare Advantage market have investors questioning if valued-based care companies are at risk.

A Breakthrough Botanical Formula Backed by 2025 Nobel Research Offers Lasting Relief from Ear Ringing and Auditory Imbalance ...

Finding legitimate work-from-home (WFH) jobs can feel like searching for a needle in a haystack. Between vague job ...